BMS-777607: c-Met Inhibitor for Cancer and Platelet Research

Principle Overview: Mechanistic Precision in MET Signaling Pathway Inhibition

BMS-777607 is a potent, orally available, ATP-competitive inhibitor that selectively targets the MET kinase family—including c-Met, Axl, Ron, and Tyro3—with nanomolar IC50 values (c-Met: 3.9 nM, Axl: 1.1 nM, Ron: 1.8 nM, Tyro3: 4.3 nM) (source: product_spec). Its selectivity is approximately 40-fold greater for these kinases over Lck, VEGFR-2, and TrkA/B, and exceeds 500-fold against other kinases, ensuring minimal off-target effects in complex cellular environments. Mechanistically, this compound impairs auto-phosphorylation of c-Met, thereby disrupting downstream signaling pathways that drive tumor growth, metastasis, and, as recent studies suggest, megakaryocyte (MK) differentiation and platelet production from human induced pluripotent stem cells (hiPSCs) (source: paper).

Key Innovation from the Reference Study

The landmark study by Yue et al. introduces an optimized differentiation protocol for hiPSC-derived MKs and platelets, incorporating small molecule supplementation—including BMS-777607—to enhance efficiency and yield. The protocol’s novelty lies in its use of BMS-777607 during the MK polyploidization phase, which significantly accelerates maturation and boosts the functional platelet output while reducing reliance on costly cytokines (source: paper). By substituting traditional cytokines with targeted kinase inhibitors (such as BMS-777607), the workflow gains both cost-effectiveness and reproducibility. For researchers, this translates to a streamlined, scalable approach for generating clinically relevant platelets or dissecting MET pathway contributions in various disease models.

Step-by-Step Workflow: Protocol Enhancements with BMS-777607

Leveraging BMS-777607 as a selective c-Met kinase inhibitor for cancer research and advanced cell models enables precise modulation of MET signaling. The following protocol steps synthesize best practices from the reference study and APExBIO’s product recommendations:

1. Embryoid Body (EB) Formation: Begin with a higher initial EB cell count to promote robust megakaryocyte lineage commitment (source: paper).
2. Culture Medium Optimization: Employ a serum-free medium, supplemented with human platelet lysate (HPL), to provide essential growth factors and minimize batch variability.
3. Small Molecule Supplementation: Add BMS-777607 during the late differentiation window to enhance MK polyploidization. Combine with other small molecules (e.g., blebbistatin, 616452) for maximal effect, as demonstrated in the study.
4. Platelet Harvest and Activation: Validate platelet functionality with thrombin-induced fibrin clot formation and contraction assays.

This protocol not only reduces differentiation time to 19 days but also improves output to 1.42 CD41+ MKs and 14.9 platelets per iPSC—representing a 58.3% cost reduction compared to conventional cytokine-driven methods (source: paper).

Protocol Parameters

• Small molecule (BMS-777607) concentration | 10 μM | MK polyploidization phase in hiPSC differentiation | Effectively abolishes basal autophosphorylation of c-Met in murine KHT cells and promotes MK maturation | product_spec, paper
• Incubation temperature | 37 °C | All stages requiring compound dissolution and cell culture | Ensures optimal solubility and physiological relevance | workflow_recommendation
• Stock solution preparation | ≥25.65 mg/mL in DMSO | Preparation of BMS-777607 for cell-based assays | Achieves maximal solubility and stability; warming and ultrasonic shaking recommended | product_spec
• Oral administration (in vivo model) | 25 mg/kg/day | KHT xenograft mouse model for metastasis suppression | Significantly reduces lung tumor nodules by 28.3% without systemic toxicity | product_spec

Advanced Applications and Comparative Advantages

Beyond its established role in cancer metastasis models, BMS-777607 is now driving innovation in regenerative medicine. Its dual functionality—MET pathway inhibition in tumor biology and facilitation of iPSC-derived platelet production—enables cross-domain studies that were previously out of reach. For example, in metastatic cancer research, BMS-777607’s ability to suppress tumor nodules and improve morphology is well-documented (source: product_spec). Meanwhile, its application in megakaryocyte polyploidization addresses the persistent bottleneck of low platelet yields in ex vivo manufacturing workflows (source: paper).

Compared to conventional methods reliant on cytokine cocktails, the small molecule-driven paradigm powered by BMS-777607 ensures greater reproducibility, scalability, and cost-effectiveness. This is particularly valuable for laboratories aiming to translate bench protocols into clinical-grade bioproducts.

Interlinking with Existing Resources:

• Optimizing hiPSC-Derived Platelet Production with Small Molecules complements this workflow, detailing how kinase inhibitors streamline production and reduce costs.
• BMS-777607: Advanced Paradigms in c-Met Inhibition for Cancer and Platelet Bioproduction extends the mechanistic insights and links protocol optimization with translational outcomes.
• BMS-777607: Selective c-Met Inhibitor for Advanced Cell Models offers protocol troubleshooting and comparative performance data, reinforcing the reproducibility and selectivity advantages of sourcing from APExBIO.

Troubleshooting & Optimization Tips

Despite the robust selectivity and efficacy of BMS-777607, experimental success depends on attention to several technical variables:

• Solubility and Handling: BMS-777607 is insoluble in water and ethanol but dissolves readily in DMSO when warmed to 37 °C and subjected to ultrasonic shaking. Prepare fresh stock solutions at ≥25.65 mg/mL and avoid prolonged storage once dissolved to maintain potency (source: product_spec).
• Compound Delivery: For in vivo studies, ensure accurate dosing (25 mg/kg/day) and monitor for systemic toxicity—none was observed in referenced mouse models (source: product_spec).
• Assay Controls: When using BMS-777607 in cell-based assays, include both negative (vehicle-only) and positive (standard cytokine) controls to distinguish kinase-specific effects from baseline differentiation variability.
• Batch Variability: Source BMS-777607 from trusted suppliers such as APExBIO to minimize batch-to-batch inconsistency and assure data reproducibility (source: workflow_recommendation).
• Readout Selection: Employ multiple readouts—microscopy, flow cytometry for CD41/CD42b, and functional clot contraction assays—to confirm both MK and platelet maturation.

Why This Cross-Domain Matters, Maturity, and Limitations

The dual utility of BMS-777607 in cancer and stem cell research exemplifies a new era of cross-disciplinary innovation. Its performance in both metastatic tumor suppression and hiPSC-derived platelet bioproduction broadens the toolkit for translational scientists seeking integrated solutions. However, this bridge is still maturing: while in vitro and in vivo preclinical results are compelling, clinical translation—especially in regenerative medicine—remains to be validated. Researchers should interpret data within the context of model-specific nuances and remain vigilant for potential off-target effects in novel applications (source: extension).

Future Outlook

Ongoing advances in MET signaling pathway inhibition are set to enhance both oncology and regenerative workflows. As highlighted by the reference study and corroborated by recent protocol guides, integrating BMS-777607 into hiPSC differentiation pipelines promises to resolve bottlenecks in platelet manufacturing, reduce reliance on expensive cytokines, and improve functional yield (source: paper). In cancer research, leveraging this c-Met inhibitor to dissect metastasis mechanisms or develop combination therapies continues to offer high translational value. For both domains, sourcing high-quality compounds from APExBIO remains a critical step toward experimental success and reproducibility.